Global Information
회사소개 | 문의 | 위시리스트

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : 제품 파이프라인 리뷰

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

리서치사 Global Markets Direct
발행일 2016년 08월 상품 코드 314194
페이지 정보 영문 36 Pages
가격
US $ 1,500 ₩ 1,776,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,552,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,329,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : 제품 파이프라인 리뷰 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
발행일 : 2016년 08월 페이지 정보 : 영문 36 Pages

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd는 생물의약품을 연구, 개발, 제조, 제품화하고 있습니다. 제품에는 유전자공학 의약품, 광선역학요법 제품, 리포솜, 의료용 진단 제품 등이 있습니다.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.의 치료제 개발 파이프라인 현황과 각 개발 단계 비교 분석, 표적·작용기전·투여 경로·분자 종류별 치료제 평가, 최신 기업 뉴스와 발표, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 전해드립니다.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : 기본 정보

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.의 개요
  • 주요 정보
  • 기업 정보

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : R&D 개요

  • 주요 치료 범위

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : 파이프라인 리뷰

  • 개발 단계별 파이프라인 제품
  • 단독치료(Monotherapy) 제품
  • 공동 개발 제품
    • 공동 개발 제품/병용요법 모달리티

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : 파이프라인 제품 상황 개요

  • 임상시험 단계 파이프라인 제품
    • 제2상 제품/병용요법 모달리티
    • 제1상 제품/병용요법 모달리티
  • 초기 단계 파이프라인 제품
    • 전임상 단계 제품/병용요법 모달리티
    • Drug Discovery 단계 제품/병용요법 모달리티

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : 치료제 개요

  • rhLT28-171
  • Hitenercept
  • rhPTH 1-34
  • vincristine sulfate liposomal
  • Fderceptin
  • Nifeviroc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : 파이프라인 분석

  • 표적별
  • 투여 경로별
  • 분자 종류별
  • 작용기전별

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : 최근의 파이프라인 동향

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : 개발이 중지된 파이프라인 제품

  • 개발이 중지된 파이프라인 제품 개요
    • Nifeviroc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. : 본사와 자회사 소재지

부록

도표

LSH 14.10.20

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's, 'Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • The report provides overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Snapshot
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Drug Profiles
    • aminolevulinic acid hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Hitenercept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • T-0001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vincristine sulfate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Fderceptin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CD30 for Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • paclitaxel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Analysis
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Target
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Projects
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Nifeviroc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Information
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Facts
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase II, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase I, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Preclinical, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Unknown, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
Back to Top
전화 문의
F A Q